Update Pharmaceutical company, Inc. is a clinical-stage small molecule company focused on developing overlooked or underutilized anti-cancer drugs. Our lead compound UPI-928 was originally developed more than 20 years ago. It has demonstrated clinical activity and good tolerability in acute myeloid leukemia (AML) and other oncology indications including refractory breast cancer, myeloma, and ovarian cancer.
News from John Rothman:
Update Pharma to Present at the 15th Annual Rodman & Renshaw Global Investment Conference
RENO, Nev., Sept. 6, 2013 /PRNewswire/ — Update Pharma Inc., today announced it will be featured as a presenting company at the 15thAnnual Rodman & Renshaw Global Investment Conference on September 10, 2013 at 3:15 pm in room 7-03 of the Millennium Hotel. The presentation will be webcast live, and the replay will remain available for […]
Update to deliver "Re-Discovering UPI-928" presentation at the 3rd World Conference on Cancer Science and Therapy on October 21 in San Francisco RENO, Nev., Aug. 13, 2013 /PRNewswire/ — Update Pharma, Inc. ("Update") announced that the company will make an oral presentation entitled "Re-Discovering UPI-928" at the 3rd World Conference on Cancer Science and Therapy on […]
